What are the common domestic indications and therapeutic effects of Cabozantinib?

Cabozantinib (Cabozantinib) is a multi-target tyrosine kinase inhibitor (TKI) with a wide range of anti-tumor effects. In recent years, it has demonstrated significant efficacy in the treatment of multiple solid tumors. The drug has been approved for marketing in my country and is widely used in the treatment of a variety of advanced solid tumors, especially in the field of renal cell carcinoma and medullary thyroid cancer, and has attracted great attention from clinicians and patients.

1. Main indications of cabozantinib

Currently in China, the main indications for cabozantinib include the following aspects:

1.Advanced renal cell carcinoma (RCC)

Cabozantinib is one of the important targeted drugs currently used to treat advanced renal cell carcinoma. According to clinical studies (such as the METEOR study), cabozantinib has shown significant advantages over everolimus in terms of progression-free survival (PFS) and overall survival (OS) for patients who have failed previous anti-angiogenic treatments, and is therefore widely recommended as a second-line treatment for these patients. In addition, cabozantinib also shows excellent efficacy for some patients with advanced RCC who have not received systemic treatment, especially in combination immunotherapy regimens.

2.Local advanced or metastatic medullary thyroid carcinoma (MTC)

For patients with medullary thyroid cancer whose RET mutation is negative or whose RET gene status is unknown, cabozantinib is recommended as a treatment option. Studies have shown that cabozantinib can significantly delay tumor progression, improve quality of life, and have a better control effect on bone metastasis, lymph node metastasis and other accompanying symptoms. Especially for advanced patients with unresectable disease, cabozantinib has become an effective targeted therapy.

3.Hepatocellular carcinoma (HCC)

Although this indication has not yet been fully liberalized in China, cabozantinib has been included in international guidelines as a second-line treatment option for advanced liver cancer. In the CELESTIAL study, cabozantinib significantly improved median progression-free survival and overall survival in patients with advanced HCC who had received sorafenib treatment. Therefore, cabozantinib is also an important treatment option for some liver cancer patients treated abroad or in clinical trials.

2. Evaluation of the therapeutic effect of cabozantinib

The reason why cabozantinib can show excellent efficacy in multiple tumor types is mainly because its mechanism of action covers multiple key tumor-related targets, such as MET, VEGFR, AXL, RET, etc. These targets play key roles in tumor angiogenesis, cell proliferation, metastasis, and drug resistance. Therefore, through multi-target blockade, cabozantinib can effectively inhibit tumor growth and metastasis.

In a number of large international clinical studies, cabozantinib has demonstrated high objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) data. For example, in the METEOR trial, the median PFS for patients with advanced kidney cancer treated with cabozantinib was 7.4 months, compared with the control drug everolimus. n>3.8 months; the median OS was 21.4 months, which was significantly better than the 16.5 months in the control group.

In the treatment of medullary thyroid cancer, the EXAM study also proved that cabozantinib can significantly delay disease progression, with the median PFS reaching 11.2 months, while the control group was only 4 months.

However, it is worth noting that although the therapeutic effect of cabozantinib is good, some patients may experience a certain degree of side effects, such as hypertension, hand-foot syndrome, oral mucositis, fatigue, loss of appetite, etc. Therefore, close monitoring is required during the medication process, and dosage adjustments are made when necessary to improve treatment compliance and quality of life.

3. Current status and prospects of domestic drug use

At present, cabozantinib has been successfully launched in China, but it has not yet been fully included in the national medical insurance directory, and some indications are still being expanded. Patients can obtain medicines through hospital prescriptions, and some provinces and cities are also actively promoting their inclusion in local medical insurance, thereby reducing the financial burden on patients.

At the same time, due to the relatively low prices of foreign generic drugs, some patients with greater financial pressure will also purchase generic versions through overseas channels. For example, generic cabozantinib from Laos or India is much cheaper than the domestic original drug, and its efficacy is basically the same as the original drug. However, it still needs to be carefully screened in terms of purchasing channels, drug supervision, and efficacy guarantee.

In the future, as more indications are approved in China and medical insurance policies are gradually improved, cabozantinib is expected to provide effective and affordable treatment options for more Chinese patients. Especially in the context of the increasing trend of combined targeted and immune therapies, the multi-target advantages of cabozantinib may bring more treatment possibilities to patients with advanced solid tumors.

In summary, cabozantinib has demonstrated good efficacy and broad indications in the treatment of advanced solid tumors, especially in the field of renal cell carcinoma and medullary thyroid cancer, with clear clinical value. With the advancement of domestic marketing and medical insurance policies, cabozantinib is expected to bring survival benefits and improve the quality of life to more cancer patients. However, professional doctors still need to be guided during the medication process to reasonably assess the risks and efficacy to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.drugs.com/